3 products found

MDxHealth products

ConfirmMDx - Actionable Molecular Diagnostic System for Prostate Cancer

ConfirmMDx Addresses Prostate Biopsy Sampling Error and the False-Negative Biopsy Dilemma. “Rule-in” high-risk men who have had a previous negative biopsy result, may be harboring undetected cancer (a false-negative biopsy result), and therefore may benefit from a repeat biopsy and appropriate treatment. “Rule-out” otherwise cancer-free men from undergoing unnecessary repeat biopsies and screening procedures, helping to reduce complications, patient anxiety, and excessive healthcare expenses associated with these procedures.

SelectMDx - Actionable Molecular Diagnostic System for Prostate Cancer

SelectMDx Helps Physicians Determine if a Patient is at Higher or Lower Risk for Prostate Cancer and Which Men Can Safely Avoid Biopsy. A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1).¹ The test provides binary results that, when combined with the patient’s clinical risk factors, help the physician determine whether:

MdxHealth - Methylation-Specific PCR Technology (MSP)

MDxHealth’s technology platform is called methylation-specific PCR (MSP), which is a proprietary DNA-based technology that functions on standard commercial PCR equipment. MSP is extremely powerful and accurate with the ability to detect a single cancer cell among 10,000 healthy cells in any type of bodily fluid or tissue. MDxHealth has patents and other intellectual property on the MSP platform and on a broad portfolio of biomarkers targeted at individual genes that are used in its different products.